☰

Jacob R. Haling, Ph.D. - Publications

Affiliations: 
2010 Molecular Pathology University of California, San Diego, La Jolla, CA 
Area:
Cell Biology, Molecular Biology, Biochemistry
Tree Info Similar researchers PubMed Report error

19 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Sudhakar N, Yan L, Qiryaqos F, Engstrom LD, Laguer J, Calinisan A, Hebbert A, Waters L, Moya K, Bowcut V, Vegar L, Ketcham JM, Ivetac A, Smith CR, Lawson JD, ... ... Haling J, et al. The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading. Molecular Cancer Therapeutics. OF1-OF13. PMID 38904222 DOI: 10.1158/1535-7163.MCT-23-0870  0.446
2024 Sudhakar N, Yan L, Qiryaqos F, Engstrom LD, Laguer J, Calinisan A, Hebbert A, Waters L, Moya K, Bowcut V, Vegar L, Ketcham JM, Ivetac A, Smith CR, Lawson JD, ... ... Haling J, et al. The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading. Molecular Cancer Therapeutics. PMID 38641404 DOI: 10.1158/1535-7163.MCT-23-0870  0.407
2024 Sudhakar N, Yan L, Qiryaqos F, Engstrom LD, Laguer J, Calinisan A, Hebbert A, Waters L, Moya K, Bowcut V, Vegar L, Ketcham JM, Ivetac A, Smith CR, Lawson JD, ... ... Haling J, et al. The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading. Molecular Cancer Therapeutics. PMID 38641404 DOI: 10.1158/1535-7163.MCT-23-0870  0.407
2022 Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, Trinh D, Hoffman N, Wang X, David Lawson J, Gunn RJ, ... ... Haling JR, et al. Anti-tumor efficacy of a potent and selective non-covalent KRAS inhibitor. Nature Medicine. PMID 36216931 DOI: 10.1038/s41591-022-02007-7  0.307
2019 Ramurthy S, Taft BR, Aversa RJ, Barsanti P, Burger MT, Lou Y, Nishiguchi G, Rico A, Setti L, Smith A, Subramanian S, Tamez VNA, Tanner HR, Wan L, Hu C, ... ... Haling J, et al. Design and Discovery of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (LXH254)- A selective, efficacious and well-tolerated RAF inhibitor targeting RAS mutant cancers: The path to the clinic. Journal of Medicinal Chemistry. PMID 31059256 DOI: 10.1021/Acs.Jmedchem.9B00161  0.432
2018 Shao W, Mishina Y, Feng Y, Caponigro G, Cooke VG, Rivera S, Wang Y, Shen F, Korn JM, Mathews Griner L, Nishiguchi G, Rico A, Tellew J, Haling J, Aversa R, et al. Antitumor properties of RAF709, a highly selective and potent inhibitor of RAF kinase dimers, in tumors driven by mutant RAS or BRAF. Cancer Research. PMID 29343524 DOI: 10.1158/0008-5472.Can-17-2033  0.508
2018 Stuart DD, Shao W, Mishina Y, Feng Y, Caponigro G, Cooke VG, Rivera S, Shen F, Korn J, Griner LAM, Nishiguchi G, Taft B, Wan L, Subramanian S, Lou Y, ... ... Haling JR, et al. Abstract DDT01-04: Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ddt01-04  0.521
2017 Emery CM, Monaco KA, Wang P, Balak MN, Freeman A, Meltzer J, Delach S, Rakiec D, Ruddy DA, Korn JM, Haling J, Acker MG, Caponigro G. BRAF-inhibitor associated MEK Mutations Increase RAF-dependent and-independent Enzymatic Activity. Molecular Cancer Research : McR. PMID 28655712 DOI: 10.1158/1541-7786.Mcr-17-0211  0.465
2017 Nishiguchi GA, Rico A, Tanner HR, Aversa RJ, Taft BR, Subramanian S, Setti L, Burger MT, Wan L, Tamez VNA, Smith A, Lou Y, Barsanti PA, Appleton BA, Mamo M, ... ... Haling JR, et al. Design and Discovery of N-(2-methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A potent, selective and efficacious RAF inhibitor targeting RAS mutant cancers. Journal of Medicinal Chemistry. PMID 28557458 DOI: 10.1021/Acs.Jmedchem.6B01862  0.47
2014 Haling JR, Sudhamsu J, Yen I, Sideris S, Sandoval W, Phung W, Bravo BJ, Giannetti AM, Peck A, Masselot A, Morales T, Smith D, Brandhuber BJ, Hymowitz SG, Malek S. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. Cancer Cell. 26: 402-13. PMID 25155755 DOI: 10.1016/J.Ccr.2014.07.007  0.504
2013 Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R, Hewitt JF, Zak M, Peck A, Orr C, Merchant M, Hoeflich KP, Chan J, Luoh SM, Anderson DJ, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 501: 232-6. PMID 23934108 DOI: 10.1038/Nature12441  0.448
2013 Haling JR, Sudhamsu J, Hatzivassiliou G, Song K, Belvin M, Hymowitz S, Malek S. Abstract LB-60: The BRAF:MEK complex reveals new therapeutic strategies for targeting KRASMTtumors. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-60  0.501
2013 Shiva M, Haling JR, Sudhamsu J, Morales T, Peck A, Yen I, Brandhuber B, Hymowitz S. Abstract 2346: A B-RAF-MEK complex reveals a kinase-independent role for BRAF in MAPK pathway suppression. Cancer Research. 73: 2346-2346. DOI: 10.1158/1538-7445.Am2013-2346  0.463
2013 Hatzivassiliou G, Haling J, Chen H, Song K, Luoh S, Price S, Heald R, Zak M, Merchant M, Hoeflich K, Friedman L, Malek S, Belvin MP. Abstract 2340: Preferential targeting of KRAS mutant or BRAF mutant tumors using MEK inhibitors with distinct mechanisms of action. Cancer Research. 73: 2340-2340. DOI: 10.1158/1538-7445.Am2013-2340  0.458
2011 Ring C, Ginsberg MH, Haling J, Pendergast AM. Abl-interactor-1 (Abi1) has a role in cardiovascular and placental development and is a binding partner of the alpha4 integrin. Proceedings of the National Academy of Sciences of the United States of America. 108: 149-54. PMID 21173240 DOI: 10.1073/Pnas.1012316108  0.456
2011 Haling JR, Monkley SJ, Critchley DR, Petrich BG. Talin-dependent integrin activation is required for fibrin clot retraction by platelets. Blood. 117: 1719-22. PMID 20971947 DOI: 10.1182/Blood-2010-09-305433  0.327
2010 Haling JR, Wang F, Ginsberg MH. Phosphoprotein enriched in astrocytes 15 kDa (PEA-15) reprograms growth factor signaling by inhibiting threonine phosphorylation of fibroblast receptor substrate 2alpha. Molecular Biology of the Cell. 21: 664-73. PMID 20032303 DOI: 10.1091/Mbc.E09-08-0659  0.539
2009 Anthis NJ, Haling JR, Oxley CL, Memo M, Wegener KL, Lim CJ, Ginsberg MH, Campbell ID. β integrin tyrosine phosphorylation is a conserved mechanism for regulating talin-induced integrin activation Journal of Biological Chemistry. 284: 36700-36710. PMID 19843520 DOI: 10.1074/Jbc.M109.061275  0.52
2007 Goldfinger LE, Ptak C, Jeffery ED, Shabanowitz J, Han J, Haling JR, Sherman NE, Fox JW, Hunt DF, Ginsberg MH. An experimentally derived database of candidate Ras-interacting proteins. Journal of Proteome Research. 6: 1806-11. PMID 17439166 DOI: 10.1021/Pr060630L  0.445
Show low-probability matches.